Coronavirus company news summary – Sanofi to support production of Pfizer/BioNTech Covid-19 vaccine – GSK, Lilly and Vir team up on antibody combination therapies

28 January 2021 (Last Updated January 28th, 2021 08:36)

28 January 2021

Sanofi and BioNTech have entered into an agreement, where the former will support the manufacturing and supply of BioNTech’s Covid-19 vaccine, which has been co-developed with Pfizer. Sanofi will support to BioNTech produce more than 125 million doses of the vaccine in Europe. The company will supply the initial doses from its Frankfurt production facilities from the summer of 2021.

Eli Lilly, Vir Biotechnology and GlaxoSmithKline are collaborating to evaluate the efficacy and safety of bamlanivimab (LY-CoV555) along with VIR-7831 (GSK4182136) to treat low-risk patients suffering with mild or moderate Covid-19 symptoms. The BLAZE-4 trial will evaluate the combination therapy to fight the SARS-COV-2 virus and marks the first initiative taken by more than one company to combine their monoclonal antibodies for Covid-19.

Aji Bio-Pharma and Humanigen will be expanding their manufacturing agreement for the fill finish supply of Lenzilumab, the latter’s drug candidate that prevents and treats the cytokine storm associated with Covid-19. The drug is currently in Phase III development for treating hospitalised Covid-19 patients.